Floatz logo

435 assets in Melanoma

Therapeutic assets addressing Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
68ga-psma
Melanoma
Royal Marsden NHS Foundation TrustP2CCC (53)
Abiraterone
Melanoma
MacroGenicsP2CCC (53)
Avapritinib
Melanoma
M.D. Anderson Cancer CenterP2CCC (53)
Disitamab Vedotin
Melanoma
RemeGen Co., Ltd.P2CCC (53)
Evx-01
Melanoma
Evaxion Biotech A/SP2CCC (53)
Fapi-46
Melanoma
Barbara Malene FischerP2CCC (53)
Gadopiclenol
Melanoma
University of ZurichP2CCC (53)
Indocyanine Green
Melanoma
M.D. Anderson Cancer CenterP1CCC (53)
Iscib1
Melanoma
Scancell LtdP2CCC (53)
L19IL2/L19TNF
Melanoma
Philogen S.p.A.P2CCC (53)
Recombinant Human Hyaluronidase
Melanoma
Emory UniversityP2CCC (53)
Rigosertib
Melanoma
Vanderbilt-Ingram Cancer CenterP2CCC (53)
Spartalizumab
Melanoma
SOLTI Breast Cancer Research GroupP3CCC (53)
Catequentinib
Melanoma
Hunan Cancer HospitalP2CCC (52)
Cifurtilimab
Melanoma
Seagen Inc.P2CCC (52)
Cobolimab
Melanoma
GlaxoSmithKlineP2CCC (52)
Decitabine
Melanoma
University of Colorado, DenverP1/2CCC (52)
Dostarlimab
Melanoma
GlaxoSmithKlineP2CCC (52)
eik1001
Melanoma
Eikon TherapeuticsP2/3CCC (52)
Human Faecal Matter
Melanoma
The Netherlands Cancer InstituteP1/2CCC (52)
Leflunomide
Melanoma
N.N. Petrov National Medical Research Center of OncologyP2CCC (52)
Mesna
Melanoma
James Isaacs, MDP2CCC (52)
Niraparib
Melanoma
Tempus AIP2CCC (52)
Sfx-01 (Sulforaphane Stabilized With .Alpha. Cyclodextrin)
Melanoma
Eastern Cooperative Oncology GroupP2CCC (52)
Sirolimus
Melanoma
National Cancer Institute (NCI)P1/2CCC (52)
t3011
Melanoma
ImmVira Pharma Co. LtdP2CCC (52)
Tiragolumab
Melanoma
University Medical Center GroningenP2CCC (52)
Tranexamic Acid
Melanoma
University of AarhusP3CCC (52)
Trastuzumab Emtansine
Melanoma
Ascendis Pharma Oncology Division A/SP2CCC (52)
Vidutolimod
Melanoma
National Cancer Institute (NCI)P2/3CCC (52)
Young Til
Melanoma
National Cancer Institute (NCI)P2CCC (52)
Zimberelimab
Melanoma
Diwakar DavarP2CCC (52)
Botensilimab
Melanoma
Agenus Inc.P2CCC (51)
Endostatin
Melanoma
Fudan UniversityP2CCC (51)
hlx208
Melanoma
Shanghai Henlius BiotechP2CCC (51)
Lbl-007
Melanoma
Nanjing Leads Biolabs Co.,LtdP1/2CCC (51)
lm103 tils
Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.P2CCC (51)
Maat013
Melanoma
Assistance Publique - Hôpitaux de ParisP2CCC (51)
Mesalamine
Melanoma
AHS Cancer Control AlbertaP2CCC (51)
Moviprep
Melanoma
Assistance Publique - Hôpitaux de ParisP2CCC (51)
Tivumecirnon
Melanoma
RAPT Therapeutics, Inc.P2CCC (51)
Tumor Antigen Loaded Autologous Dendritic Cells
Melanoma
Sichuan UniversityP1/2CCC (51)
Ulixertinib
Melanoma
UNC Lineberger Comprehensive Cancer CenterP2CCC (51)
YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
Melanoma
Eucure (Beijing) Biopharma Co., LtdP2CCC (51)
18f-flt
Melanoma
ECOG-ACRIN Cancer Research GroupP2CCC (50)
Avelumab
Melanoma
TILT Biotherapeutics Ltd.P2CCC (50)
Dasatinib
Melanoma
National Cancer Institute (NCI)P2CCC (50)
jpb898
Melanoma
SandozP3CCC (50)
Naporafenib
Melanoma
Erasca, Inc.P3CCC (50)
Vancomycin
Melanoma
Microbiotica LtdP1/2CCC (49)
Showing 101 to 150 of 435 assets
PreviousPage 3 of 9Next